Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H26N2O2S2 |
Molecular Weight | 402.573 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(C)(=O)=O
InChI
InChIKey=FLGCRGJDQJIJAW-UHFFFAOYSA-N
InChI=1S/C21H26N2O2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)26-21-11-10-17(15-19(21)23)27(2,24)25/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
Molecular Formula | C21H26N2O2S2 |
Molecular Weight | 402.573 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Sulforidazine (Imagotan (Sandoz); Inofal (Sandoz)) is a typical piperidine-type phenothiazine antipsychotic agent. It is dopamine receptor blocker. Being the second active metabolite of thioridazine (converted from mesoridazine), Sulforidazine is significantly more potent than the parent drug.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. | 2001 Dec |
|
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. | 2003 May |
|
Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. | 2003 Sep-Oct |
|
No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. | 2007 May |
|
Factors affecting drug concentrations and QT interval during thioridazine therapy. | 2007 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8097899
The metabolism of sulforidazine was studied in female dogs and adult male humans after oral administration of 37.5 mg and 25.0 mg, respectively.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6707914
Curator's Comment: The electrically evoked overflow of dopamine (DA) from perfused rabbit striatal slices was used to assess the relative functional potencies of thioridazine, a phenothiazine antipsychotic agent, and two of its major metabolites, mesoridazine (thioridazine-2-sulfoxide) and sulforidazine (thioridazine-2-sulfone).
Mesoridazine and sulforidazine likewise produced only small increases (5-20%) in evoked overflow of DA from slices stimulated at 0.3 Hz. At this frequency of stimulation, apomorphine (30 nM) inhibited the overflow of DA by 71.4 +/- 8.43% (n = 40). All three drugs antagonized, in a concentration-dependent fashion, the inhibitory effect of apomorphine (30 nM) on electrically evoked DA release at 0.3 Hz. The IC50 for thioridazine for antagonizing the effect of apomorphine was 130 nM, whereas that for mesoridazine was 14.4 nM and for sulforidazine was 6.1 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:53:21 GMT 2025
by
admin
on
Mon Mar 31 17:53:21 GMT 2025
|
Record UNII |
B7599I244X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10742MIG
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
DTXSID30864531
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
31765
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
SULFORIDAZINE
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
2532
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
2394
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
C040634
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
100000083767
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
238-818-7
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
C84185
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
B7599I244X
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107268
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
m10363
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
14759-06-9
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
PRIMARY | |||
|
103827-31-2
Created by
admin on Mon Mar 31 17:53:21 GMT 2025 , Edited by admin on Mon Mar 31 17:53:21 GMT 2025
|
SUPERSEDED |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY | |||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |